Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.

Détails

ID Serval
serval:BIB_C3FB14F9A4BC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
Périodique
The British journal of dermatology
Auteur(s)
Norrenberg S., Masconi M., Karamanou M., Meylan P., Golaz R., Christen-Zaech S.
ISSN
1365-2133 (Electronic)
ISSN-L
0007-0963
Statut éditorial
Publié
Date de publication
30/01/2018
Peer-reviewed
Oui
Volume
179
Numéro
1
Pages
280-209
Langue
anglais
Notes
Publication types: Letter

Résumé
The use of topical rapamycin or rapalog, an mTOR inhibitor, has shown promising results in treating facial angiofibromas (FA) in children with Tuberous Sclerosis Complex (TSC). Nevertheless, several issues remain: the effectiveness, stability and tolerability of ingredients; and the cost - the higher the concentration of rapamycin the more expensive the product. In this retrospective comparative study, children with TSC and FA were treated consecutively with three different topical rapalog compounds of 0.1%, the lowest concentration with crushed tablets to demonstrate an effect. This article is protected by copyright. All rights reserved.

Pubmed
Web of science
Création de la notice
01/02/2018 19:08
Dernière modification de la notice
25/08/2018 6:21
Données d'usage